RxDoctor Payments Data

Robert Kleiner, MD

Retina Specialist · North Wales, PANPI 1063408987

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Genentech USA, Inc. at 33.6% of the total. 2025 is the largest year on record at $727, 2.8 times the $263 reported in 2019. That places this record below the midpoint for retina specialist clinicians in PA, where the typical reported total is $2,388.

$2,388in general payments, 2019–2025

Across 142 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$802
  • Regeneron Healthcare Solutions, Inc.$529
  • Apellis Pharmaceuticals, Inc.$472
  • Astellas Pharma US Inc$276
  • AbbVie$134
  • ANI Pharmaceuticals, Inc.$85
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$2,37599%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,388 in reported general payments places this provider in the 50th percentile of 43 retina specialist providers in Pennsylvania.

See all retina specialist providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$4,268,388
Medicare patients
992
Services billed
61,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ofloxacin826$8,645
Prednisolone Acetate121$7,574
LumiganBimatoprost18$6,720
Atropine Sulfate33$1,603
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat73$1,546
MoxifloxacinMoxifloxacin Hcl58$862
Latanoprost45$575
Ketorolac Tromethamine22$458
Timolol Maleate13$319
Gentamicin Sulfate19$161
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen19$50

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$134$6,72018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 43 retina specialist providers in Pennsylvania.

Other retina specialist in North Wales

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →